GSK turns to Camp4 for neuro and kidney medicines

GSK will en­list reg­u­la­to­ry RNA biotech Camp4 Ther­a­peu­tics to help find and cre­ate new neu­rode­gen­er­a­tive and kid­ney dis­ease med­i­cines.

The deal is worth $17.5 mil­lion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.